TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial
TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial
What was tested
Treatment tested
- Tarenflurbil
Gamma-secretase modulator
What it measured
Main measures
Primary endpoint efficacy:
Other measures (1)
Secondary endpoints efficacy:
Loading reviews and guidelines…
History
- In scope changed from true to false
Started
Apr 2015
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error